...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Comparative dosimetric evaluation of the simultaneous integrated boost with photon intensity modulation in head and neck cancer patients.
【24h】

Comparative dosimetric evaluation of the simultaneous integrated boost with photon intensity modulation in head and neck cancer patients.

机译:头颈癌患者同时进行联合增强与光子强度调制的剂量学比较评估。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND PURPOSE: The objective of this study is to evaluate, at planning and dosimetric level, the potential benefits of the simultaneous integrated boost (SIB) concept with intensity-modulated radiation therapy (IMRT), using a comparative analysis on physical dose distributions corrected for radiobiological models. The concept of SIB at the end of the treatment has been analysed as an alternative acceleration scheme. PATIENTS AND METHODS: Physical dose distributions were computed on a commercial planning system (Varian Cadplan-Helios) for five patients presenting with advanced head and neck carcinomas. Treatment plans were designed using five IMRT beams. Three fractionation strategies were compared in the study: the standard sequential irradiation SEQ of elective and boost volumes, the pure SIB, and a modified SIB (SEQ/SIB), where the actual SIB follows a first phase of conventional fractionation to the elective volume. All physical dose distributions were corrected using a linear quadratic biological model, taking into account also repopulation and time at repopulation onset. Objective quantities, derived from biological dose volume histograms, were used for the analysis. RESULTS: Physical doses equivalent to 50 and 80 Gy (in fractions of 2 Gy) to elective volume and boost were calculated for the SIB and SEQ/SIB regimes. With SIB 54 and 72 Gy dose levels have to be delivered in 30 fractions, while in the SEQ/SIB scheme 36 Gy are delivered in 20 sessions to the elective volume, and further 18 and 35.5 Gy during the last 10 fractions are delivered to elective volume and boost, respectively (for a total physical dose of 71.5 Gy). The comparison showed: (1) the boost target homogeneity resulted in generally acceptable and comparable among sequential and modified SIB schemes, while it was statistically worse for the pure SIB approach; (2) the fraction of elective target volume not included in the boost volume was characterised by a higher level of dose heterogeneity; (3) the spinal cord never reached tolerance levels and maximum point dose was on average below 38 Gy (biologically corrected to 2 Gy/fraction); and (4) sparing of parotid glands strongly depends on their eventual inclusion in the target volumes: for glands not included or only partially included, it was possible on average to keep the dose to 2/3 of the volume below 29 Gy for all regimes (32 Gy as physical dose). CONCLUSIONS: Feasibility of SIB techniques and in particular of the modified SIB appears to be dosimetrically proven and the results reported here justify the activation of a phase I protocol to verify clinically their impact using IMRT photon-based techniques.
机译:背景与目的:这项研究的目的是在计划和剂量学水平上,通过对校正后的物理剂量分布进行比较分析,来评估同时集成升压(SIB)和强度调制放射疗法(IMRT)的潜在益处。用于放射生物学模型。在治疗结束时,SIB的概念已作为替代性加速方案进行了分析。患者和方法:物理剂量分布是在商业计划系统(Varian Cadplan-Helios)上针对五位患有晚期头颈癌的患者进行计算的。使用五个IMRT光束设计治疗计划。在研究中比较了三种分馏策略:选择性和增量体积的标准顺序照射SEQ,纯SIB和改良的SIB(SEQ / SIB),其中实际的SIB遵循常规分馏的第一阶段达到选择性体积。使用线性二次生物学模型校正了所有物理剂量分布,同时考虑了重新种群和重新种群发作的时间。从生物剂量体积直方图得出的客观数量用于分析。结果:对于SIB和SEQ / SIB方案,计算了等效于50和80 Gy的物理剂量(以2 Gy的分数表示)的选择性体积和增强剂量。使用SIB 54和72 Gy时,剂量水平必须分30步传递,而在SEQ / SIB方案中,在20个疗程中将36 Gy传递至选修量,而在最后10个分数中将18和35.5 Gy传递给选择性体积和增强(分别为71.5 Gy的总物理剂量)。比较结果表明:(1)提高目标的同质性在顺序和改进的SIB方案中通常可以接受并具有可比性,而在纯SIB方法中统计上更差; (2)提高剂量中不包含的选择性目标体积分数具有较高的剂量异质性特征; (3)脊髓从未达到耐受水平,最大点剂量平均低于38 Gy(生物校正为2 Gy /分数); (4)腮腺的稀疏性很大程度上取决于它们最终是否包含在目标体积中:对于不包含或仅部分包含的腺体,在所有方案中平均可以将剂量保持在29 Gy以下的体积的2/3 (32 Gy为物理剂量)。结论:SIB技术,尤其是改良的SIB技术的可行性似乎已被剂量学证实,此处报道的结果证明了使用基于IMRT光子技术的I期协议的激活以临床验证其影响的合理性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号